Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcio Marc Abreu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total Reversal of ALS Confirmed by EMG Normalization, Structural Reconstitution, and Neuromuscular–Molecular Restoration Achieved Through Computerized Brain-Guided Reengineering of the 1927 Nobel Prize Fever Therapy: A Case Report

    by M. Marc Abreu, Mohammad Hosseine-Farid, David G. Silverman

    Background: Neurological disorders are the leading cause of disability, affecting over three billion people worldwide. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring lost function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT2). This fully noninvasive treatment, delivered through an FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize-recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT2 induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins, which are known to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman was diagnosed with progressive ALS at the Mayo Clinic, with electromyography (EMG) demonstrating fibrillation and fasciculation indicative of denervation corroborated by neurological and MRI findings; the patient was informed that she had an expected survival of three to five years. A neurologist from Northwestern University confirmed the diagnosis and thus maintained the patient on FDA-approved ALS drugs (riluzole and edaravone). Her condition rapidly worsened despite pharmacological treatment, and she underwent CBIT2, resulting in (i) electrophysiological reversal with complete disappearance of denervation; (ii) biomarker correction, including reductions in neurofilament and homocysteine, IL-10 normalization (previously linked to mortality), and robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; (iv) reconstitution of tongue structure; and (v) return to complex motor tasks, including golf, pickleball, and swimming. Discussion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation, which induces heat shock response and upregulates heat shock proteins, resulting in the patient no longer meeting diagnostic criteria for ALS and discontinuation of ALS-specific medications. Beyond ALS, shared protein-misfolding pathology suggests that CBIT2 may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing this Nobel Prize-recognized therapeutic principle with computerized precision, CBIT2 establishes a framework for large-scale clinical trials. A century after fever therapy restored lost brain function and so decisively reversed dementia paralytica such that it earned the 1927 Nobel Prize in Medicine, CBIT2 now safely harnesses the therapeutic power of fever through noninvasive, intelligent, brain-guided thermal modulation. Amid a global brain health crisis, fever-based therapies may offer a path to preserve thought, memory, movement, and independence for the more than one-third of humanity currently affected by neurological disorders.

  • Open Access

    Total Reversal of ALS Confirmed by EMG Normalization and Neuromuscular–Molecular Evidence Achieved Through Computerized Brain-Guided Reengineering of the 1927 Nobel Prize Fever Therapy: A Video-Documented Case Report

    by M Marc Abreu, Mohammad Hosseini Farid, David G Silverman

    Background: Neurological disorders are the leading cause of disability, affecting over three billion people. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT²). This fully noninvasive treatment, delivered through FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize–recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT² induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman with rapidly progressive ALS was diagnosed at the Mayo Clinic, based on electromyography showing denervation and fasciculations corroborated by neurological and MRI findings; and patient was informed of an expected 3–5-year survival. Northwestern University independently confirmed the diagnosis and maintained her on FDA-approved ALS drugs (riluzole and edaravone). Her condition worsened and she underwent CBIT², resulting in: (i) electrophysiological reversal with disappearance of denervation and fasciculations; (ii) biomarker correction, including reductions in neurofilament and homocysteine, besides IL-10 normalization (previously linked to mortality) alongside robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; and (iv) return to complex motor tasks, including golf and pickleball. Discussion/Conclusion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation. Beyond ALS, shared protein-misfolding pathology suggests CBIT² may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing a Nobel Prize–recognized therapeutic principle with digital precision, CBIT² establishes a framework for large-scale clinical trials. Just as fever therapy a century ago restored lost brain function in dementia paralytica and earned the 1927 Nobel Prize, CBIT² now safely harnesses the therapeutic power of fever through brain-guided modulation. Amid a global brain health crisis, where neurological disorders affect more than three billion people, fever-based therapies may provide a path to preserve thought, memory, movement, and independence for over one third of humanity.

  • Top Cited Papers
    Open Access

    From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy

    by M. Marc Abreu, Alberto F. Chocron, David M. Smadja

    The emergence of immunotherapies has revolutionized cancer treatment by leveraging the immune system to target malignancies, offering new hope where traditional therapies often fall short. Within this context, hyperthermia (HT) has re-emerged as a promising adjunctive treatment, capable of enhancing the effectiveness of radiotherapy, chemotherapy, and immunotherapy. HT influences both the innate and adaptive immune systems, enhancing the activity of immune cells such as neutrophils, NK cells, and dendritic cells, while also modulating the tumor microenvironment (TME) to promote immunogenic cell death (ICD) and reduce immunosuppressive conditions. These effects contribute to the transformation of immunologically “cold” tumors into “hot” tumors, making them more susceptible to immune-mediated destruction. Furthermore, HT can amplify the efficacy of immune checkpoint inhibitors (ICIs) by improving immune cell infiltration, inducing damage-associated molecular pattern (DAMP) release, and enhancing antigen presentation. Preclinical and clinical studies support the combination of HT with ICIs, demonstrating improved outcomes in otherwise resistant tumors. However, the full therapeutic potential of the different technologies allowing to apply HT remains to be fully understood, and further research is needed to optimize treatment protocols, explore the differential impacts of local versus whole-body hyperthermia, and identify biomarkers for patient stratification. This review underscores the multifaceted role of HT in immunity and its potential to significantly enhance the efficacy of immunotherapy.


  • Open Access

    Hyperthermia and targeting heat shock proteins: innovative approaches for neurodegenerative disorders and Long COVID

    by David M. Smadja, M. Marc Abreu

    Neurodegenerative diseases (NDs) and Long COVID represent critical and growing global health challenges, characterized by complex pathophysiological mechanisms including neuronal deterioration, protein misfolding, and persistent neuroinflammation. The emergence of innovative therapeutic approaches, such as whole-body hyperthermia (WBH), offers promising potential to modulate underlying pathophysiological mechanisms in NDs and related conditions like Long COVID. WBH, particularly in fever-range, enhances mitochondrial function, induces heat shock proteins (HSPs), and modulates neuroinflammation—benefits that pharmacological treatments often struggle to replicate. HSPs such as HSP70 and HSP90 play pivotal roles in protein folding, aggregation prevention, and cellular protection, directly targeting pathological processes seen in NDs like Alzheimer's, Parkinson's, and Huntington's disease. Preliminary findings also suggest WBH's potential to alleviate neurological symptoms in Long COVID, where persistent neuroinflammation and serotonin dysregulation are prominent. Despite the absence of robust clinical trials, the therapeutic implications of WBH extend to immune modulation and the restoration of disrupted physiological pathways. However, the dual nature of hyperthermia's effects—balancing pro-inflammatory and anti-inflammatory responses—emphasizes the need for dose-controlled applications and stringent patient monitoring to minimize risks in vulnerable populations. While WBH shows potential interest, significant challenges remain. These include individual variability in response, limited accessibility to advanced hyperthermia technologies, and the need for standardized clinical protocols. Future research must focus on targeted clinical trials, biomarker identification, and personalized treatment strategies to optimize WBH's efficacy in NDs and Long COVID. The integration of WBH into therapeutic paradigms could mark a transformative step in addressing these complex conditions.


  • Open Access

    HSP47 at the Crossroads of Thrombosis and Collagen Dynamics: Unlocking Therapeutic Horizons and Debates

    by David M. Smadja, Alberto F. Chocron, M. Marc Abreu

    Heat shock protein 47 (HSP47), a collagen-specific molecular chaperone encoded by the SERPINH1 gene, has emerged as a groundbreaking focus in thrombosis research. Recent findings published in “Science” have revolutionized our understanding of thrombosis, identifying HSP47 as a critical mediator in a new thrombosis target for treatment. This discovery not only unveils a novel pathway in thrombosis but also opens new avenues for therapeutic intervention. HSP47's significance extends beyond thrombosis, influencing pathological processes such as fibrosis and cancer. In fibrosis, its upregulation promotes collagen deposition, while its dysregulation in osteogenesis imperfecta (OI) Type X underscores the protein's indispensable role in collagen biosynthesis. The therapeutic challenge lies in balancing HSP47 inhibition to reduce fibrotic burden without impairing its essential physiological functions. In cancer, HSP47 plays dual roles. It supports tumor progression through collagen stabilization and metastasis facilitation while contributing to tissue repair under hyperthermia treatment combined with radiotherapy or chemotherapy. However, its overexpression can exacerbate tumor aggressiveness via mechanisms such as angiogenesis and epithelial–mesenchymal transition.This review emphasizes the pivotal discovery of HSP47's thrombogenic role and its broader implications in disease biology. These findings mark a paradigm shift in thrombosis research and underscore the potential of HSP47 as a target in diverse pathological contexts, from platelet-driven diseases to fibrotic and oncological disorders.


  • Open Access

    Brain thermal kinetics at brain-eyelid thermal tunnels overcoming COVID-19 thermometry limitations for automated asymptomatic infection detection in concert with physical and biological principles

    by M Marc Abreu, Ricardo L Smith, Trevor M Banack, Alexander C Arroyo, Robert F Gochman, Anna L Clebone, Feng Dai, Michael F Bergeron, Ala S Haddadin, Tyler J Silverman, et al.

    For centuries, temperature measurement deficiencies attributable to biological barriers and low thermo-conductivity ( k ) have precluded accurate surface-based fever assessment. At this stage of the pandemic, infection detection in children (who due to immature immune system may not effectively respond to vaccines) is critical because children can be readily infected and also become a large mutation reservoir. We reveal hitherto-unrecognized worldwide body temperature measurements (T°), in children and adults, over tissue typified by low- k similar to wood that may reach 6.8°C in thermal variability, hampering thereby COVID-19 control. Brain-eyelid thermal tunnels’ (BTT) integration of low- k and high- k regions creating a thermal pathway for undisturbed heat transmission from hypothalamus to high- k skin eliminates current shortcomings and makes the brain indispensable for defeating COVID-19 given that brain thermoregulatory signals are not limited by mutations. Anatomo-histologic, emissive, physiologic, and thermometric bench-to-bedside studies characterized and overcome biophysical limitations of thermometry through high- k eyelid-enabled brain temperature measurements in children and adults. BTT eyelid features fat-free skin (~900 µm) and unique light emission through a blood/fat configuration in the underlying tunnel. Contrarily, forehead features variable and thick dermis (2000–2500 µm) and variable fat layers (1100–2800 µm) resulting in variable low- k as well as temperatures 1.97 °C lower than BTT temperature (BTT°). Highest emission present in only ~3.1% of forehead averaged 1.08±0.49 °C (mean±SD) less than BTT° ( p =0.008). Environmental and biological impacts during fanning revealed thermal imaging limitations for COVID-19 screening. Comparison of paired measurements for 100 pediatric patients showed that in the children subgroup above 37°C, BTT° exceeded body core temperature (Core°) in 60/72 patients; the average difference in the 72 patients was 0.62±0.7°C (p<0.001 by unpaired t-test); and in the subgroup beyond 37.5°C, BTT° exceeded Core° in 30/32 patients. Delineating hypothalamic activity in children facilitates early infection detection, which is essential because children’s immunogenicity prevents effective vaccination and causes accelerated viral evolution. Capturing hypothalamic thermal signals from BTT was further supported by brain thermal kinetics via BTT using wearables during anesthesia, sedation, sleep, brain injury, exercise, and asymptomatic infection, which revealed brain/core discordance and enabled automated noninvasive afebrile infection detection for interrupting asymptomatic human-to-human transmission. BTT-based spot-check thermometry can be harmlessly implemented for children worldwide without undue burden and costs; meanwhile, continuous brain-eyelid T° in concert with biological and physical principles affords a new dimension for combating pandemics. The “detection–vaccination” pair solution presented is required to mitigate COVID-19 from spreading indefinitely through mutations and vaccine evasion while opening a viable path for eradicating COVID-19.


  • Open Access

    Biophysical Basis of Thermometry Limitations to Control COVID-19 are Overcome at Transmissive Skin Overlying Brain-eyelid Thermal Tunnels

    by M Marc Abreu, Ricardo L Smith, Trevor M Banack, Anna L Clebone, Ala S Haddadin, Tyler J Silverman, Feng Dai, David G Silverman

    Essential to management of pandemics, noninvasive thermometry has been hampered by inaccuracies and inconsistencies, due to measurements on low thermal conductivity ( k ) surfaces we show here, which have precluded effective assessment of febrile states for centuries. Discovery of brain-eyelid thermal tunnels (BTT) identified undisturbed thermal transmission from brain. We here report a series of integrated anatomic, histologic, thermal emissive, thermal physiologic and thermometric studies designed to identify, characterize and overcome the biophysical limitations of surface thermometry as currently used worldwide to control COVID-19, which primarily relies on non-contact forehead thermometry. However, the forehead has thick and variable dermis (~2000 µm to ~2500 µm) and fat layers (~1100 µm to ~2800 µm) resulting in low- k insulation equivalent to wood. During thermal emission, the highest skin temperature at forehead, present in only ~3.1% of forehead, averaged 1.07±0.49°C (mean±SD) less than over BTT (p=0.008, two-tailed paired t-test). Thermometric studies (without correction factor) revealed 1.97°C higher temperature at BTT site (BTT°) than forehead. Facial fanning caused 3.5°C reduction in forehead temperature, which do not compromise BTT site, attributable to impact on non-BTT surface sites by highly variable surface vasculature. Cerebral hemisphere dominance studies uncovered higher BTT° in the dominant side (Pk thermometry can be immediately and conveniently enhanced by brain-enabled thermo-physical based high- k signal conversion, which can be easily implemented by any country, community or individual in the world.


  • Open Access

    Brain/core Discordance due to Neuronal Activity Identified by Noninvasive Brain Temperature Measurement via Brain-eyelid Thermal Tunnels

    by M Marc Abreu, Trevor M Banack, Ala S Haddadin, Tyler J Silverman, Feng Dai, John A Elefteriades, Robert Ostroff, Michael F Bergeron, David G Silverman

    We herein performed a series of brain/core temperature discordance studies in setting of brain excitation and depression to assess whether noninvasive temperature measurement at highly transmissive eyelid skin overlying newly discovered brain-eyelid thermal tunnel (BTT°) is specific for brain as opposed to core temperature (Core°). BTT°-Core° was determined during hypothermic cardiopulmonary bypass (CPB), seizures induced during electroconvulsive therapy (ECT), pharmacologic depression by sedation and anesthesia, sleep, stroke, brain trauma, and exercise in hot environmental chamber. During brain-core decoupling BTT° follows brain neuronal activity. BTT°-Core° varied dramatically due to extreme changes during CPB. During ECT, BTT° ipsilateral to induced seizure increased from 36.38±0.4°C pre-seizure to 36.69°±0.3°C at two minute post-seizure (p<0.001 by paired t-test); Core° remained within 0.01°C of baseline (p=0.2). These changes were accompanied by BTT°-Core° discordance ranging from-0.1°C pre-seizure to +0.31°C post-seizure. Alternatively, during brain neuronal depression, BTT° ipsilateral to evolving ischemic stroke and Core° were 35.37±0.2°C and 36.00±0.09°C, respectively, with p<0.0001 for BTT°-Core° of 0.63±0.13°C. These findings document specificity of BTT transmission for brain thermal energy and illustrate potential BTT° usefulness in myriad clinical and investigative settings.


  • Open Access

    Previously unseen brain-eyelid thermal tunnel reveals biological waveguide and transorbital thermophysical pathway to the brain

    by M Marc Abreu, Ricardo L Smith, Keith Ruskin, Adriano F Da Silva, Ala S Haddadin, Michael F Bergeron, Trevor M Banack, David G Silverman

    Fat is recognized as low thermoconductivity ( k ) tissue and barrier for thermal transmission. We here identify and characterize morphologically, radiologically, and thermo-physically fat-enabled bilateral integrated blood/fat/skin thermal pathways, referred as Brain-eyelid Thermal Tunnels (BTT), that enable undisturbed thermal transmission between brain and uniquely radiant high- k skin in the right and left eyelids. We elucidated cranial "aberrancies", justified the facial "death triangle" and uncovered perihypothalamic thermoregulatory-sensory triunal inherent to brain thermal homeostasis that revealed thermal communication among brain, heart, and environment. Our results introduce the first evidence for a brain↔surface thermo-physical pathway and biological thermal waveguide. Said transmission was documented by an isolated beam of emission at the ipsilateral BTT terminus. We showed brain thermal transfer via BTT during neurosurgery by comparison of noninvasive temperature measurement at the BTT site (BTT°) to direct temperature measurement in brain parenchyma (Parenchyma°) in open craniotomy (BTT° - Parenchyma° = 0.012±0.2°C, p=0.91), as opposed to 0.45°C difference between BTT° and core temperature. This indicates that BTT° provides an accurate noninvasive method for measuring human brain temperature unimpeded by the body's thermal barrier through transorbital thermo-physical configurations.


  • Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy

    by Luiz Csp Rolim, Edina Mk Da Silva, Ronald Lg Flumignan, Marcio M Abreu, Sérgio A Dib

    Background Diabetic peripheral neuropathy (DPN) is a common and severe complication that affects 50% of people with diabetes. Painful DPN is reported to occur in 16% to 24% of people with diabetes. A complete and comprehensive management strategy for the prevention and treatment of DPN, whether painful or not, has not yet been defined. Research into treatment for DPN has been characterised by a series of failed clinical trials, with few noteworthy advances. Strategies that support peripheral nerve regeneration and restore neurological function in people with painful or painless DPN are needed. The amino acid acetyl‐L‐carnitine (ALC) plays a role in the transfer of long‐chain fatty acids into mitochondria for β‐oxidation. ALC supplementation also induces neuroprotective and neurotrophic effects in the peripheral nervous system. Therefore, ALC supplementation targets several mechanisms relevant to potential nerve repair and regeneration, and could have clinical therapeutic potential. There is a need for a systematic review of the evidence from clinical trials. Objectives To assess the effects of ALC for the treatment of DPN. Search methods On 2 July 2018, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. We checked references, searched citations, and contacted study authors to identify additional studies. Selection criteria We included randomised controlled trials (RCTs) and quasi‐RCTs of ALC compared with placebo, other therapy, or no intervention in the treatment of DPN. Participants could be of any sex and age, and have type 1 or type 2 diabetes mellitus, of any severity, with painful or painless DPN. We accepted any definition of minimum criteria for DPN, in accordance with the Toronto Consensus. We imposed no language restriction. Pain was the primary outcome, measured as the proportion of participants with at least 30% (moderate) or 50% (substantial) decrease in pain over baseline, or as the score on a visual analogue scale (VAS) or Likert scale for pain. Data collection and analysis We followed standard Cochrane methods. Main results We included four studies with 907 participants, which were reported in three publications. Three trials studied ALC versus placebo (675 participants); in one trial the dose of ALC was 2000 mg/day, and in the other two trials, it was 1500 mg/day or 3000 mg/day. The fourth trial studied ALC 1500 mg/day versus methylcobalamin 1.5 mg/day (232 participants). The risk of bias was high in both trials of different ALC doses and low in the other two trials. No included trial measured the proportion of participants with at least moderate (30%) or substantial (50%) pain relief. ALC reduced pain more than placebo, measured on a 0‐ to 100‐mm VAS (MD ‐9.16, 95% CI ‐16.76 to ‐1.57; three studies; 540 participants; P = 0.02; I² = 56%; random‐effects; very low‐certainty evidence; a higher score indicating more pain). At doses of 1500 mg/day or less, the VAS score after ALC treatment was little different from placebo (MD ‐0.05, 95% CI ‐10.00 to 9.89; two studies; 159 participants; P = 0.99; I² = 0%), but at doses greater than 1500 mg/day, ALC reduced pain more than placebo (MD ‐14.93, 95% CI ‐19.16 to ‐10.70; three studies; 381 participants; P < 0.00001; I² = 0%). This subgroup analysis should be viewed with caution as the evidence was even less certain than the overall analysis, which was already of very low certainty. Two placebo‐controlled studies reported that vibration perception improved after 12 months. We graded this evidence as very low certainty, due to inconsistency and a high risk of bias, as the trial authors did not provide any numerical data. The placebo‐controlled studies did not measure functional impairment and disability scores. No study used validated symptom scales. One study performed sensory testing, but the evidence was very uncertain. The fourth included study compared ALC with methylcobalamin, but did not report effects on pain. There was a reduction from baseline to 24 weeks in functional impairment and disability, based on the change in mean Neuropathy Disability Score (NDS; scale from zero to 10), but there was no important difference between the ALC group (mean score 1.66 ± 1.90) and the methylcobalamin group (mean score 1.35 ± 1.65) groups (P = 0.23; low‐certainty evidence). One placebo‐controlled study reported that six of 147 participants in the ALC > 1500 mg/day group (4.1%) and two of 147 participants in the placebo group (1.4%) discontinued treatment because of adverse events (headache, facial paraesthesia, and gastrointestinal disorders) (P = 0.17). The other two placebo‐controlled studies reported no dropouts due to adverse events, and more pain, paraesthesia, and hyperaesthesias in the placebo group than the 3000 mg/day ALC group, but provided no numerical data. The overall certainty of adverse event evidence for the comparison of ALC versus placebo was low. The study comparing ALC with methylcobalamin reported that 34/117 participants (29.1%) experienced adverse events in the ALC group versus 33/115 (28.7%) in the methylcobalamin group (P = 0.95). Nine participants discontinued treatment due to adverse events (ALC: 4 participants, methylcobalamin: 5 participants), which were most commonly gastrointestinal symptoms. The certainty of the adverse event evidence for ALC versus methylcobalamin was low. Two studies were funded by the manufacturer of ALC and the other two studies had at least one co‐author who was a consultant for an ALC manufacturer. Authors' conclusions We are very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with DPN, when compared with placebo, as the...